Insider · CIK 0001790246
Sanjay Subramanian
cfoofficer
Files at SCYX (SCYNEXIS INC), INZY (Inozyme Pharma, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | SCYX SCYNEXIS INC | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | 31 d ago |
| Jul 1, 2025 | INZY Inozyme Pharma, Inc. | UTender of shares Common Stock | -39,701 | $4.00 | $159k | 0 | Jul 3, 2025 |
| Jul 1, 2025 | INZY Inozyme Pharma, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -38,500 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | INZY Inozyme Pharma, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -180,000 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | INZY Inozyme Pharma, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -135,000 | - | - | 0 | Jul 3, 2025 |
| Jul 1, 2025 | INZY Inozyme Pharma, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -145,000 | - | - | 0 | Jul 3, 2025 |
| Jun 25, 2025 | INZY Inozyme Pharma, Inc. | AGrant or award Common Stock | +6,813 | $0.74 | $5,042 | 39,701 | Jun 27, 2025 |
| Mar 31, 2025 | INZY Inozyme Pharma, Inc. | AGrant or award Common Stock | +2,490 | $0.77 | $1,917 | 32,888 | Apr 2, 2025 |
| Mar 11, 2025 | INZY Inozyme Pharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +145,000 | $0.00 | $0 | 145,000 | Mar 17, 2025 |
| Mar 11, 2025 | INZY Inozyme Pharma, Inc. | AGrant or award Restricted Stock Unitsderivative | +38,500 | $0.00 | $0 | 38,500 | Mar 17, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.